Decitabine

TP53 Gene Mutation

Northside Hospital, Inc.Small moleculePhase 2Active

B

58/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 45/ 100
Competitive Position: 81/ 100

Competitive context

5 Active assets in the TP53 Gene Mutation cohort.

Asset / Sponsor	Phase	Rating
Cedazuridine The University of Hong Kong	Phase 2	CCC
Azacitidine The University of Hong Kong	Phase 2	CCC
Arsenic Trioxide The University of Hong Kong	Phase 2	CCC
Epirubicin City of Hope Medical Center	Phase 1	CC
Pembrolizumab City of Hope Medical Center	Phase 1	CC

Same molecule, other indications

Decitabine is also rated in:

disease related to hematopoietic stem cell transplantDormant

BBB

Indicative ·

72 / 100

acute myeloid leukemia with t(8;21)(q22;q22) translocationDormant

BB

Indicative ·

70 / 100

acute myeloid leukemiaDormant

BB

Indicative ·

70 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.